Association of serum steroid levels with survival in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel on ECOG-ACRIN E3805.

被引：0
|
作者：
Mostaghel, Elahe A.
Wang, Xin Victoria
Marck, Brett
Matsumoto, Alvin M.
Sweeney, Christopher
机构：
[1] VA Puget Sound Hlth Care Syst, Seattle, WA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
146
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805
    Morgans, Alicia K.
    Chen, Yu-Hui
    Jarrard, David F.
    Carducci, Michael
    Liu, Glenn
    Eisenberger, Mario
    Plimack, Elizabeth R.
    Bryce, Alan
    Garcia, Jorge A.
    Dreicer, Robert
    Vogelzang, Nicholas J.
    Picus, Joel
    Shevrin, Daniel
    Hussain, Maha
    DiPaola, Robert S.
    Cella, David
    Sweeney, Christopher J.
    PROSTATE, 2022, 82 (12): : 1176 - 1185
  • [2] Changes in bone turnover markers (BTM) and association with outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) plus /- docetaxel (D) in CHAARTED (ECOG-ACRIN E3805).
    McGregor, Bradley Alexander
    Wang, Xin Victoria
    Hamnvik, Ole-Petter R.
    Cheung, Yee Ming
    Wei, Xiao X.
    Ravi, Praful
    Fichorova, Raina N.
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [3] Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.
    Tripathi, Abhishek
    Chen, Yu-Hui
    Jarrard, David Frazier
    Hahn, Noah M.
    Garcia, Jorge A.
    Dreicer, Robert
    Liu, Glenn
    Hussain, Maha H. A.
    Shevrin, Daniel H.
    Cooney, Matthew M.
    Eisenberger, Mario A.
    Kohli, Manish
    Plimack, Elizabeth R.
    Vogelzang, Nicholas J.
    Picus, Joel
    Carducci, Michael Anthony
    DiPaola, Robert S.
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
    Halabi, Susan
    Roy, Akash
    Guo, Siyuan S.
    Rydzewska, Larysa
    Godolphin, Peter
    Hussain, Maha H. A.
    Tangen, Catherine
    Thompson, Ian
    Xie, Wanling
    Carducci, Michael Anthony
    Smith, Matthew Raymond
    Morris, Michael J.
    Gravis, Gwenaelle
    Dearnaley, David P.
    Verhagen, Paul
    Goto, Takayuki
    Tierney, Jayne F.
    James, Nicholas D.
    Buyse, Marc E.
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer
    Mostaghel, Elahe A.
    Wang, Victoria
    Marck, Brett T.
    Sharifi, Nima
    Matsumoto, Alvin M.
    Sweeney, Christopher J.
    ENDOCRINE-RELATED CANCER, 2025, 32 (02)
  • [6] Lower PSA at 7 months is prognostic for improved overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel (D).
    Harshman, Lauren Christine
    Chen, Yu-Hui
    Liu, Glenn
    Carducci, Michael Anthony
    Jarrard, David Frazier
    Dreicer, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [7] Prognostic validation of a digital pathology-based multi-modal artificial intelligence (MMAI) biomarker in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the CHAARTED trial (ECOG-ACRIN EA3805)
    Markowski, Mark Christopher
    Ren, Yi
    Croucher, Danielle
    Royce, Trevor Joseph
    Yamashita, Rikiya
    Tierney, Meghan
    Huang, Huei-Chung
    Todorovic, Tamara
    Chen, Emmalyn
    Carducci, Michael Anthony
    Chen, Yu-Hui
    Liu, Glenn
    Parker, Charles
    Esteva, Andre
    Feng, Felix Y.
    Attard, Gerhardt
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).
    Smith, Matthew Raymond
    Saad, Fred
    Hussain, Maha
    Sternberg, Cora N.
    Fizazi, Karim
    Yamada, Karin Sayuri
    Kappeler, Christian
    Kuss, Iris
    Tombal, Bertrand F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [9] Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC).
    Gill, David Michael
    Stenehjem, David D.
    Cheng, Heather H.
    Kessler, Elizabeth Riley
    Hahn, Andrew W.
    Gupta, Sumati
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [10] Impact of prior definitive therapy on survival outcomes in men with new hormone-sensitive metastatic prostate cancer (mHSPC).
    Alex, Anitha
    Stenehjem, David D.
    Twardowski, Przemyslaw
    Cheng, Heather H.
    Gill, David Michael
    Buckley, Tyler Howard
    Patel, Shiven B.
    Kessler, Elizabeth Riley
    Chittoria, Namita
    Poudel, Aarati
    Vaishampayan, Ulka N.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345